Business Wire

Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors

27.4.2023 17:00:00 EEST | Business Wire

Share

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.

Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010.

These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.

The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models. Dendritic cells primed by STC-1010 will induce a multi specific pool of T-lymphocytes against the tumor without toxicity.

The second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors’ isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo.

Taken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC.

Innovative in vivo model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay.

Session Title: Clinical Research Excluding Trials - Vaccines

Abstract Presentation Number: 6791

STC-1010 a new therapeutic vaccine promotes tumor cell death.

Session Title: Late-Breaking Research: Immunology 2

Abstract Presentation Number: LB224

For further information:

https://www.brenus-pharma.com/
https://explicyte.com/
https://www.inovotion.com/

1 STC-1010 is a next-generation cancer vaccine immunotherapy that targets tumor antigens and is produced by Allogeneic STC's proprietary Brenus platform. It’s the lead candidate specifically designed to combat colorectal cancer (CRC) including MSS and MSI-H populations in its first line of treatment for the first indication.
2 Inovotion Biopolis- 5 av du Grand Sablon, 38700 La Tronche, France
3 Brenus Pharma Parc industriel Tech Lavaur La Bechade 63 500 Issoire, France
4 Center Georges François Leclerc, 1 rue du Pr Marion 21000 Dijon, France
5 Explicyte 229 Cours de l'Argonne, 33000 Bordeaux
6 Institut Bergonie 229 Cours de l'Argonne, 33000 Bordeaux

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CONTACT BRENUS

Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%19.4.2024 18:13:00 EEST | Press release

Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419226980/en/ e4life: e4ambient and e4you devices (Photo: Business Wire) This is a perfect occasion for e4life to present its device based on the e4shield technology which is able to inactivate flu and Covid viruses present in the air. A technology, patented in Italy, that uses neither chemical agents nor filtering materials, but it is based on the transmission of electromagnetic waves able to inactivate the viral load in aerosol. “This Exhibition represents an extraordinary opportunity to present our innovative technology (e4shield) in a dynamic and rapidly evolving region as Eurasia. In a climate of growing consciousness of the

Qualcomm Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call19.4.2024 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its second quarter fiscal 2024 on Wednesday, May 1, 2024, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its second quarter fiscal 2024 results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/events. An audio replay will be available at https://investor.qualcomm.com/news-events/events and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use rese

Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer19.4.2024 15:56:00 EEST | Press release

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Francois Hardy as Chief Technology Officer (CTO). Francois will join Newmont’s Executive Leadership Team and lead the technical work across the business to improve operational performance and drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419973025/en/ Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer (Photo: Business Wire) Francois will take over from interim CTO, Dean Gehring, who also served in a dual role as Newmont’s Chief Integration Officer. After a period of transition, Dean will be leaving the company in early July. Francois brings more than 30 years of technical and operational experience in mining to the role. He commenced with Newmont in 2002 and has held roles including Group Head Exploration, Managing Director Africa and General Manager Tanami. “Francois is a stron

SLB Announces First-Quarter 2024 Results, Targeting to Return $7 Billion to Shareholders Over 2024–202519.4.2024 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced results for the first-quarter 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417469361/en/ The exterior of the SLB headquarters in Houston, Texas (Photo: Business Wire) First-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2024 Dec. 31, 2023 Mar. 31, 2023 Sequential Year-on-year Revenue $8,707 $8,990 $7,736 -3% 13% Income before taxes - GAAP basis $1,357 $1,433 $1,161 -5% 17% Income before taxes margin - GAAP basis 15.6% 15.9% 15.0% -35 bps 58 bps Net income attributable to SLB - GAAP basis $1,068 $1,113 $934 -4% 14% Diluted EPS - GAAP basis $0.74 $0.77 $0.65 -4% 14% Adjusted EBITDA* $2,057 $2,277 $1,788 -10% 15% Adjusted EBITDA margin* 23.6% 25.3% 23.1% -171 bps 51 bps Pretax segment operating income* $1,649 $1,868 $1,391 -12% 19% Pretax segment operating margin* 18.9% 20.8% 18.0% -184 bps 95 bps Net income attributable to SLB, exclud

Zayo Group Appoints New CEO of Zayo Europe19.4.2024 10:00:00 EEST | Press release

Zayo Group, a leading global provider of network infrastructure, has appointed Colman Deegan as its new CEO of Zayo Europe to drive the business’ growth as cloud and AI adoption continues across the continent. This appointment is effective as of April 16, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419471253/en/ Colman Deegan, CEO Zayo Europe (Photo: Business Wire) Steve Smith, CEO Zayo Group, says, “Colman’s experience and proven track record as a CEO leading large teams and businesses makes him perfectly equipped to take our European business to new heights, together with our outstanding local team. Colman will drive Zayo forward, strengthening our partnerships with data centres, hyperscalers, and enterprises across Europe. Under Colman’s leadership, we are confident that we will achieve our bold ambitions and maximise our impact in the European market.” Deegan spent more than two decades at Vodafone where he h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye